PROstaTE Cancer Treatment and Obesity in Zoladex-Astrazeneca Treated Patients
- Conditions
- Prostate CancerObesity
- Registration Number
- NCT01020604
- Lead Sponsor
- AstraZeneca
- Brief Summary
The reports on relationship of obesity and biochemical or clinical recurrence of prostate cancer are controversial. Several reports have shown that obesity is associated with increased risk of biochemical or clinical failure after radical prostatectomy. Other prospective studies have shown no adverse effect of obesity on long-term outcomes after prostatectomy. Limited reports are available on the impact of obesity on prostate cancer progression after radiotherapy. Primary: to assess percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy. Secondary: to determine the Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 1376
- Histologically proven prostate cancer patients being on adjuvant Zoladex treatment after primary therapy or on adjuvant therapy without primary curative therapy
-Prostate cancer patients refractory to hormonal therapy, not agreeing to participate, allergy against treatment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage recurrence rate among normal weight and overweight or obese prostate cancer patients treated by adjuvant Zoladex therapy. Every 3 months
- Secondary Outcome Measures
Name Time Method Quality of Life differences among normal and overweight or obese prostate cancer patients by a Quality of Life questionnaire Every 3 months
Trial Locations
- Locations (1)
Research Site
ðŸ‡ðŸ‡ºVeszprem, Hungary